ReviewOncotarget2022
Early-onset pancreatic cancer: a review of molecular mechanisms, management, and survival.
Review in Oncotarget, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- The Association between Early-Onset Pancreatic Ductal Adenocarcinoma and Patients Survival: A Systematic Review and Meta-Analysis.F1000Research · 2024Pooled it
- Disease Burden of Early-Onset Pancreatic Cancer in Adults Aged 20-54 Years in Low- and Middle-Income Countries: A GBD 2023 Analysis.Digestive diseases and sciences · 2026Article
- Clinicopathological differences and risk factors of early- versus late-onset pancreatic cancer: A systematic review and meta-analysis.iScience · 2026Article
- Article
- Temporal Trends in Pancreatic Cancer in New South Wales, Australia: A Longitudinal Population-Based Study of Incidence, Surgery and Survival.ANZ journal of surgery · 2026Article
- Review
- Temporal trends in cross-country inequalities of early-onset pancreatic cancer: a comprehensive analysis for the global burden of disease study 2021.Scientific reports · 2025Article
- Global burden of early-onset pancreatic cancer attributable to metabolic risks from 1990 to 2021, and projections to 2030.Frontiers in oncology · 2025Article
- Baicalein inhibits DDX60 to suppress pancreatic cancer growth and regulate the tumor microenvironment.American journal of translational research · 2025Article
- Aspects and outcomes of surveillance for individuals at high-risk of pancreatic cancer.Familial cancer · 2024Review
- Treatment patterns and survival outcomes in patients with non-metastatic early-onset pancreatic cancer.World journal of gastroenterology · 2024Article
- Early-onset gastrointestinal cancer: An epidemiological reality with great significance and implications.World journal of gastrointestinal oncology · 2024Article
- Microsatellite Instability Is Insufficiently Used as a Biomarker for Lynch Syndrome Testing in Clinical Practice.JCO precision oncology · 2024Article
- Multiomic Characterization Reveals a Distinct Molecular Landscape in Young-Onset Pancreatic Cancer.JCO precision oncology · 2023Article
- The Global Burden of Early-Onset Biliary Tract Cancer: Insight From the Global Burden of Disease Study 2019.Journal of clinical and experimental hepatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesEarly-onset pancreatic cancer (EOPC) - defined as pancreatic cancer diagnosed before the age of 50 years - is associated with a poor prognosis as compared to later-onset pancreatic cancer (LOPC). Emerging evidence suggests that EOPC may exhibit a genetic signature and tumor biology that is distinct from that of LOPC. We review genetic mutations that are more prevalent in EOPC relative to LOPC and discuss the potential impact of these mutations on treatment and survival. MATERIALS AND
methodsUsing PubMed and Medline, the following terms were searched and relevant citations assessed: "early onset pancreatic cancer," "late onset pancreatic cancer," "pancreatic cancer," "pancreatic cancer genes," and "pancreatic cancer targeted therapy."
resultsMutations in
conclusionsGenetic mutations associated with EOPC are distinct from those of LOPC. The preponderance of the evidence suggest that poor outcomes in EOPC are related both to advanced stage of presentation and unique tumor biology. The molecular and genetic features of EOPC warrant further investigation in order to optimize management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.